# Boehringer Ingelheim (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/boehringer-ingelheim-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 26.2 |
| Citations | 785,366 |
| City | Ridgefield |
| Country | US |
| Description | Boehringer Ingelheim (United States) is a research organisation in Ridgefield, US. OpenAlex records 6,479 works and 785,366 citations for it. 1,672 researchers list it as their most recent affiliation. |
| Homepage | http://us.boehringer-ingelheim.com/ |
| OpenAlex ID | https://openalex.org/I4210160255 |
| Region | Connecticut |
| Researchers | 1,672 |
| ROR ID | https://ror.org/05kffp613 |
| Type | company |
| Works | 6,479 |

## University papers

Showing 12 of 40.

- [Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-cardiovascular-outcomes-and-mortality-in-type-2-diabetes/)
- [Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-and-progression-of-kidney-disease-in-type-2-diabetes/)
- [Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus](https://scholariq.org/papers/renal-hemodynamic-effect-of-sodium-glucose-cotransporter-2-inhibition-in/)
- [Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients](https://scholariq.org/papers/metabolic-response-to-sodium-glucose-cotransporter-2-inhibition-in-type-2/)
- [Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial](https://scholariq.org/papers/heart-failure-outcomes-with-empagliflozin-in-patients-with-type-2-diabetes-at/)
- [Adipokines and Insulin Resistance](https://scholariq.org/papers/adipokines-and-insulin-resistance/)
- [Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/efficacy-and-safety-of-empagliflozin-added-to-existing-antidiabetes-treatment-in/)
- [Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes](https://scholariq.org/papers/effects-of-empagliflozin-on-blood-pressure-and-markers-of-arterial-stiffness-and/)
- [Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease](https://scholariq.org/papers/empagliflozin-and-clinical-outcomes-in-patients-with-type-2-diabetes-mellitus/)
- [The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus](https://scholariq.org/papers/the-effect-of-empagliflozin-on-arterial-stiffness-and-heart-rate-variability-in/)
- [Bat Guano Virome: Predominance of Dietary Viruses from Insects and Plants plus Novel Mammalian Viruses](https://scholariq.org/papers/bat-guano-virome-predominance-of-dietary-viruses-from-insects-and-plants-plus/)
- [Metagenomic Analyses of Viruses in Stool Samples from Children with Acute Flaccid Paralysis](https://scholariq.org/papers/metagenomic-analyses-of-viruses-in-stool-samples-from-children-with-acute/)

## University researchers

- [Uli C. Broedl](https://scholariq.org/researchers/uli-c-broedl/)
- [Joseph Victoria](https://scholariq.org/researchers/joseph-victoria/)
- [B.M.K. Donato](https://scholariq.org/researchers/b-m-k-donato/)

## University top topics

Showing 8 of 25.

- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)
- [Chronic Obstructive Pulmonary Disease (COPD) Research](https://scholariq.org/topics/chronic-obstructive-pulmonary-disease-copd-research/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Computational Drug Discovery Methods](https://scholariq.org/topics/computational-drug-discovery-methods/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.